Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho

Kootenai Health - Coeur d'Alene is a clinical research site located in Coeur d'Alene, Idaho, United States 83814.

Crixeo Clinical Trials Trust Score: 35/100 (FAILING). This profile has not yet been claimed by the site owner.

Kootenai Health - Coeur d'Alene has participated in 242 clinical trials with 202 currently active.

Therapeutic areas: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Sponsors: National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Coeur d'Alene

Browse all research sites in Idaho · View every site in Coeur d'Alene

Sponsor Feasibility Report

Trust Score: 35/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Kootenai Health - Coeur d'Alene?

Kootenai Health - Coeur d'Alene has a Crixeo Trust Score of 35/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Kootenai Health - Coeur d'Alene conducted?

Kootenai Health - Coeur d'Alene has 242 clinical trials on record, with 202 currently active. Their work covers Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Is Kootenai Health - Coeur d'Alene accredited by Crixeo Clinical Trials?

Kootenai Health - Coeur d'Alene has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Kootenai Health - Coeur d'Alene?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.